Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in Portugal

Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for HR+/HER2- Advanced/Metastatic Breast Cancer in Portugal

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07223476

Acronym

PORTRAIT

Enrollment

1926

Registered

2025-10-31

Start date

2024-03-29

Completion date

2024-07-01

Last updated

2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

Cyclin-dependent Kinase 4/6 Inhibitor, Real-world

Brief summary

Assess and characterize the real-world cyclin-dependent kinase 4/6 inhibitor (CDKI) use in advanced/metastatic breast cancer (a/mBC), evaluate treatment persistence, and quantify CDKI dose adjustments in Portugal. This study used secondary data from the IQVIA database that collects data from hospital drug consumption. The study included 16 public hospitals across Portugal, for which data on consumption of drugs used in hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) a/mBC treatment was available. Patient selection was based on a set of criteria considering all patients with treatments in the a/mBC setting with use of at least one CDKI from November 2018 to May 2023.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Male and female patients of all ages. * Patients with at least one CDKI consumption from November 2018 to May 2023. * Patients with consumptions in Gynecology and Oncology specialties.

Exclusion criteria

* Consumption patterns of target drugs that are not compatible with any known a/mBC treatment regimen. * Patients in early stages of breast cancer.

Design outcomes

Primary

Measure	Time frame	Description
Number of Patients Treated With a CDKI Between November 2018 and May 2023	Up to approximately 4 years and 6 months	—
Median Treatment Duration	Up to approximately 4 years and 6 months	—
Median Time to Next Treatment (TTNT)	Up to approximately 4 years and 6 months	TTNT was calculated considering the time between the start of one treatment line and the start of the next treatment line.
Number of Patients With Dose Reductions by Treatment Length per Line of Treatment	Up to approximately 4 years and 6 months	Patients were categorized as having 0, 1, or 2 dose reductions over 0-6 months, 7-12 months, and 12 months or more of treatment.

Countries

United States

Outcome results